Sunshine Lake Pharma Unveils Three Innovative Oncology Drug Candidates at 2026 AACR Annual Meeting

Key Points and Strategic Highlights for Investors

• Three advanced preclinical drug candidates were showcased at the 2026 AACR Annual Meeting:
  • HEC-922: CDH17/4-1BB bispecific antibody for precision tumor immune activation
  • HEC234055: Orally available high-activity pan-RAS molecular glue inhibitor targeting multiple KRAS mutations
  • HEC201625: Orally available small-molecule PD-L1 inhibitor with potential best-in-class efficacy
• Demonstrates the Group’s diversified technology platforms and sustained innovation capabilities, including TCE technology, precision targeting, and tumor immunotherapy small molecules.
• Potential for First-in-Class (FIC) or Best-in-Class (BIC) status in multiple programs, with a focus on overcoming “undruggable” targets and combination synergies in oncology.
• Significant preclinical data supporting strong efficacy, broad spectrum activity, safety, and potential for combination therapies.
• Strategic focus on major tumor types such as gastrointestinal, prostate, and kidney cancers, aiming for substantial clinical benefits.
• Company plans further R&D investment, clinical translation, and international collaboration to accelerate development and commercialization of these candidates.
• Risk Warning: All data are preclinical; drug candidates have not entered human clinical trials. High uncertainty remains regarding eventual approval and commercialization.

Drug Candidate Details

1. HEC-922 — CDH17/4-1BB Bispecific Antibody

• Constructed using Fc-silenced humanized nanobody technology for conditional activation of 4-1BB signaling within CDH17-positive tumor microenvironment.
• Significant anti-tumor activity: Outperformed 4-1BB monoclonal antibody in CDH17-positive models.
• Remodels tumor immune microenvironment: Restores immune cell function, reduces PD-1+ exhausted T cells.
• Synergy with PD-1 antibody: Combination therapy further enhances anti-tumor efficacy.
• Superior safety window: Animal studies show safety window up to 300–500 times; related molecule HEC-921 verified high NOAEL (100 mg/kg in cynomolgus monkey).

2. HEC234055 — Orally Available Pan-RAS Molecular Glue Inhibitor

• Targets a broad spectrum of KRAS mutations (G12D, G12C, G12V, G13D, Q61H, wild-type amplification).
• Binds both active (GTP-bound) and inactive (GDP-bound) states of KRAS.
• Sub-nanomolar cell activity: IC50 as low as 0.49 nM in multiple KRAS-driven cancer cell lines; superior to current benchmarks.
• Significant in vivo efficacy: Dose-dependent tumor inhibition and regression in pancreatic, lung, and colorectal cancer xenograft models.
• Addresses significant unmet clinical needs in cancers driven by KRAS mutations, a traditionally “undruggable” target.

3. HEC201625 — Orally Available Small-Molecule PD-L1 Inhibitor

• Induces PD-L1 dimerization and internalization, blocking PD-1/PD-L1 signaling and activating T-cell-mediated anti-tumor responses.
• Potent immune activation: EC90 ~21 nM in NFAT reporter assays, superior to reference molecules.
• Excellent in vivo efficacy: Up to 70% tumor growth inhibition rate in MC38-hPDL1 and PBMC humanized models.
• Superior efficacy in PD-L1 antibody-insensitive models (non-small cell lung cancer, triple-negative breast cancer).
• Broad combination potential: Shows synergy with 5-FU, anti-VEGF, VEGFR inhibitors, KRAS G12C inhibitors.
• Good pharmacokinetics and safety: Oral bioavailability confirmed; hERG inhibition IC50 >10 μM; safety window >90 times in 28-day GLP study.

Strategic Implications and Potential Share Price Impact

• The showcase of these three innovative preclinical oncology drug candidates underscores Sunshine Lake Pharma’s commitment to cutting-edge cancer therapeutics and its competitive positioning in the global pharmaceutical market.
• First-in-class and best-in-class potential in these programs could unlock significant commercial opportunities if clinical translation is successful.
• Focus on “undruggable” targets and combination regimens addresses substantial unmet clinical needs, which may increase investor confidence in the company’s pipeline.
• Plans for increased R&D investment, clinical trials, and international collaboration could catalyze future value creation and partnership opportunities.
• However, all data are preclinical; none of the candidates have entered human trials. The risk of failure remains high, and there is no guarantee of eventual approval or commercialization.
• Investors should monitor further announcements regarding clinical progress, regulatory milestones, and partnership developments.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All information is based on preclinical data; none of the drug candidates discussed have entered human clinical trials. Drug development is subject to substantial risk and uncertainty. Investors should exercise caution and consult professional advisors before making investment decisions related to Sunshine Lake Pharma Co., Ltd.

View SUNSHINE PHARMA Historical chart here